TiumBio presents Phase 2a interim data for Tosposertib plus pembrolizumab at ASCO 2026

ImmVira reports 100% CRR at 9 months in bladder carcinoma in situ with MVR-T3011

CARsgen presents long-term satri-cel follow-up results at 2026 ASCO Annual Meeting

Hanmi signs licensing deal with Lilly for sonefpeglutide

AstraZeneca secures US approval for Imfinzi–BCG regimen in high‑risk bladder cancer

Innovent Biologics and Pfizer agree global collaboration to develop innovative oncology medicines

FDA approves TREMFYA label expansion

Phanes Therapeutics reports updated Phase 2 results for spevatamig (PT886) in combination with chemotherapy

GSK reports positive phase III data for bepirovirsen in chronic hepatitis B

Sanofi's venglustat receives FDA priority review for type 3 Gaucher disease

Antengene receives Chinese clearance for Phase III study of ATG-022 in CLDN18.2+ advanced gastric/GEJ cancer

Ribo submits Phase 2 trial application for RBD1119 to European regulator

US FDA extends review timeline for AstraZeneca's camizestrant application

Circio and AaviGen partner to develop next-generation gene therapies for heart disease

CordenPharma acquires AmbioPharm, expanding peptide API capacity